Building upon the success of the American Gene Technologies® HIV clinical trial, Addimmune will singularly focus on developing and commercializing an effective and lasting cure for HIV using gene and cell therapy. CEO Jeff Galvin announced encouraging results from the Phase 1 clinical trial which spurred the creation of Addimmune. To celebrate, several hundred leaders and stakeholders from Montgomery County and beyond joined our team in commemorating this major milestone.
Send this to friend
*By downloading the Insight, The Art of Tweeting you are also joining our newsletter.